Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.

[1]  W. Howard.  Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease preventionZhou Z, Rahme E, Pilote L (McGill Univ, Montréal; Montréal Gen Hosp) Am Heart J 151:273–281, 2006§ , 2007 .

[2]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[3]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[4]  E. Topol.  Intensive statin therapy--a sea change in cardiovascular prevention. , 2004, The New England journal of medicine.

[5]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[6]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[7]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[8]  J. Larosa.  New and emerging data from clinical trials of statins , 2004, Current atherosclerosis reports.

[9]  J. Tu,et al.  Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. , 2003, The Canadian journal of cardiology.

[10]  A. Keech,et al.  Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. , 2003, Diabetes care.

[11]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[12]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[13]  A. Tonkin,et al.  Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. , 2003, American heart journal.

[14]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[15]  A. Whitehead.  Dealing with Heterogeneity , 2003 .

[16]  A. Whitehead.  Meta‐Analysis Using Individual Patient Data , 2003 .

[17]  A. Whitehead.  Combining Estimates of a Treatment Difference Across Trials , 2003 .

[18]  J. Mckenney,et al.  Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial , 2003, Current medical research and opinion.

[19]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[20]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[21]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[22]  David Colquhoun,et al.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.

[23]  B. Davis,et al.  Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. , 2002, European heart journal.

[24]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[25]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[26]  I. Marschner,et al.  Long-term risk stratification for survivors of acute coronary syndromes - Results from the long-term intervention with pravastatin in ischemic disease (LIPID) study , 2001 .

[27]  J. LeLorier,et al.  Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.

[28]  J. Tu,et al.  Did the major clinical trials of statins affect prescribing behaviour? , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  A. Tonkin,et al.  Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial , 2001, Annals of Internal Medicine.

[30]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[31]  J. Tu,et al.  Use of the statins in patients after acute myocardial infarction: does evidence change practice? , 2001, Archives of internal medicine.

[32]  L. Fisher,et al.  Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. , 2001, American heart journal.

[33]  David Hunt,et al.  Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study , 2000, The Lancet.

[34]  C. Mulrow,et al.  Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials , 2000, BMJ : British Medical Journal.

[35]  A. Keech,et al.  Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project , 2000, Circulation.

[36]  D G Altman,et al.  Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. , 2000, Controlled clinical trials.

[37]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[38]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[39]  D L Sackett,et al.  Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. , 1999, JAMA.

[40]  B. Davis,et al.  Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.

[41]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[42]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[43]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[44]  R. Ferrer,et al.  Graphical methods for detecting bias in meta-analysis. , 1998, Family medicine.

[45]  M. Pfeffer,et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.

[46]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[47]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[48]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[49]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[50]  A Whitehead,et al.  Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.

[51]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[52]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[53]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[54]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[55]  D. Ingram,et al.  Statistics in Practice , 1983 .